Wilms tumour (WT) is one of the cancer types targeted by the Global Initiative for Childhood Cancer (GICC). The objective of this study was to describe the outcomes of Wilms Africa Phase II in sub-Saharan Africa.

Methods

Wilms Africa Phase II used a comprehensive WT treatment protocol in a multi-centre, prospective study conducted in eight hospitals in Ethiopia (2), Ghana (2), Malawi, Cameroon, Zimbabwe and Uganda. Eligibility criteria were: age younger than 16 years, unilateral WT, diagnosed between 1 January 2021 and 31 December 2022.

Results

We included 230 WT patients, median age 3 years, 53% male. Median maximum tumour diameter at diagnosis was 13.6 cm and 33% of patients had metastatic disease. Nephrectomy was performed in 71% of patients, of whom 21% had a tumour rupture. Two-year event-free survival (EFS) was 41.3% ± 3.9% after a median follow-up of 17 months (range: 1–33 months), with treatment abandonment considered an event. Treatment abandonment occurred in 26% and death during treatment in 14%. Disease relapse occurred in 10%. Two-year EFS of the 26 patients who received radiotherapy was 64.5% ± 9.7% with no reported disease relapse.

Conclusion

Patients continue to present late with advanced WT in sub-Saharan Africa, and their survival is below the 60% GICC target. Prevention of treatment abandonment and treatment-related mortality remain important. Earlier diagnosis and access to radiotherapy are expected to decrease disease-related mortality.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflicts of interest.

Open Research

DATA AVAILABILITY STATEMENT

Data available on request from the authors.

REFERENCES

1Nakata K, Colombet M, Stiller CA, Pritchard-Jones K, Steliarova-Foucher E, Contributors IICC-3. Incidence of childhood renal tumours: an international population-based study. Int J Cancer. 2020; 147(12): 3313-3327.
10.1002/ijc.33147
CAS PubMed Web of Science® Google Scholar
2 World Health Organization. CureAll framework: WHO Global Initiative for Childhood Cancer. Increasing access, advancing quality, saving lives. WHO; 2021.
Google Scholar
3Dome JS, Graf N, Geller JI, et al. Advances in Wilms tumor treatment and biology: progress through international collaboration. J Clin Oncol. 2015; 33(27): 2999-3007.
10.1200/JCO.2015.62.1888
CAS PubMed Web of Science® Google Scholar
4Abuidris DO, Elimam ME, Nugud FM, Elgaili EM, Ahmed ME, Arora RS. Wilms tumour in Sudan. Pediatr Blood Cancer. 2008; 50(6): 1135-1137.
10.1002/pbc.21547
PubMed Web of Science® Google Scholar
5Moreira C, Nachef MN, Ziamati S, et al. Treatment of nephroblastoma in Africa: results of the first French African Pediatric Oncology Group (GFAOP) study. Pediatr Blood Cancer. 2012; 58(1): 37-42.
10.1002/pbc.23284
CAS PubMed Web of Science® Google Scholar
6Israels T, Pidini D, Borgstein E, et al. Survival of children with a Wilms tumor in Blantyre, Malawi. Pediatr Hematol Oncol. 2018; 35(3): 196-202.
10.1080/08880018.2018.1498564
PubMed Web of Science® Google Scholar
7van Heerden J, Balagadde-Kambugu J, Angom R, et al. Evaluating the baseline survival outcomes of the "six Global Initiative for Childhood Cancer index cancers" in Africa. Pediatr Hematol Oncol. 2023; 40(3): 203-223.
10.1080/08880018.2022.2140860
PubMed Web of Science® Google Scholar
8Chagaluka G, Paintsil V, Renner L, et al. Improvement of overall survival in the Collaborative Wilms Tumour Africa Project. Pediatr Blood Cancer. 2020; 67(9):e28383.
10.1002/pbc.28383
PubMed Web of Science® Google Scholar
9Holmes DM, Matatiyo A, Mpasa A, et al. Outcomes of Wilms tumor therapy in Lilongwe, Malawi, 2016–2021: successes and ongoing research priorities. Pediatr Blood Cancer. 2023; 70(5):e30242.
10.1002/pbc.30242
CAS PubMed Web of Science® Google Scholar
10Uittenboogaard A, Njuguna F, Mostert S, et al. Outcomes of Wilms tumor treatment in western Kenya. Pediatr Blood Cancer. 2022; 69(4):e29503.
10.1002/pbc.29503
PubMed Web of Science® Google Scholar
11Ekenze SO, Nwangwu EI, Ezomike UO, Orji EI, Okafor OO. Continuing barriers to care of Wilms tumor in a low-income country. Pediatr Blood Cancer. 2019; 66(1):e27416.
10.1002/pbc.27416
PubMed Web of Science® Google Scholar
12Ekenze SO, Okafor OC, Obasi AA, Okafor DC, Nnabugwu II. Wilms tumor in Africa: a systematic review of management challenges and outcome in two decades (2000–2019). Pediatr Blood Cancer. 2020; 67(11):e28695.
10.1002/pbc.28695
PubMed Web of Science® Google Scholar
13 International Society of Paediatric Oncology. Wilms Africa webpage 2023. International Society of Paediatric Oncology; 2023. Accessed June 20, 2024. https://siop-online.org/collaborative-wilms-tumour-africa-project/
Google Scholar
14 International Society of Paediatric Oncology. CANCaRe Africa—The Collaborative African Network for Childhood Cancer Care and Research 2023. International Society of Paediatric Oncology; 2023. Accessed June 20, 2024. https://siop-online.org/cancareafrica/
Google Scholar
15Paintsil V, David H, Kambugu J, et al. The Collaborative Wilms Tumour Africa Project; baseline evaluation of Wilms tumour treatment and outcome in eight institutes in sub-Saharan Africa. Eur J Cancer. 2015; 51(1): 84-91.
10.1016/j.ejca.2014.10.030
PubMed Web of Science® Google Scholar
16Israels T, Paintsil V, Nyirenda D, et al. Improved outcome at end of treatment in the collaborative Wilms tumour Africa project. Pediatr Blood Cancer. 2018; 65(5):e26945.
10.1002/pbc.26945
PubMed Web of Science® Google Scholar
17Israels T, Moreira C, Scanlan T, et al. SIOP PODC: clinical guidelines for the management of children with Wilms tumour in a low-income setting. Pediatr Blood Cancer. 2013; 60(1): 5-11.
10.1002/pbc.24321
CAS PubMed Web of Science® Google Scholar
18 Wilms Africa Phase II treatment guideline 2023. International Society of Paediatric Oncology; 2023. Accessed June 20, 2024. https://siop-online.org/wp-content/uploads/2020/04/Treatment-Guidelines-Collaborative-Wilms-Tumour-Africa-Project-Phase-II-doc-v1.8-FINAL.pdf
Google Scholar
19Shyirambere C, Villaverde C, Nguyen C, et al. Nephroblastoma treatment and outcomes in a low-income setting. J Glob Oncol. 2022; 8:e2200036.
10.1200/GO.22.00036
PubMed Google Scholar
20Tournade MF, Com-Nougue C, de Kraker J, et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms’ tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms’ Tumor Trial and Study. J Clin Oncol. 2001; 19: 488-500.
10.1200/JCO.2001.19.2.488
CAS PubMed Web of Science® Google Scholar
21Israels T, Afungchwi GM, Chagaluka G, et al. Early death and treatment-related mortality: a report from SUCCOUR—Supportive Care for Children with Cancer in Africa. Pediatr Blood Cancer. 2021; 68(9):e29230.
10.1002/pbc.29230
PubMed Web of Science® Google Scholar
22Israels T, Chagaluka G, Pidini D, et al. The efficacy and toxicity of SIOP preoperative chemotherapy in Malawian children with a Wilms tumour. Pediatr Blood Cancer. 2012; 59(4): 636-641.
10.1002/pbc.24088
PubMed Web of Science® Google Scholar
23Graf N, Tournade MF, de Kraker J. The role of preoperative chemotherapy in the management of Wilms’ tumor. The SIOP studies. International Society of Pediatric Oncology. Urol Clin North Am. 2000; 27: 443-454.
10.1016/S0094-0143(05)70092-6
CAS PubMed Web of Science® Google Scholar
24Israels T, Arora RS, Sung L. The value of reporting on end-of-treatment outcome of patients in low-income settings. Pediatr Blood Cancer. 2023; 70(12):e30686.
10.1002/pbc.30686
PubMed Web of Science® Google Scholar
25Atwiine B, Mdoka C, Branchard M, et al. Prevention of treatment abandonment remains an important challenge to increase survival of Wilms tumor in sub-Saharan Africa: a report from Wilms Africa-CANCaRe Africa. Pediatr Blood Cancer. 2024; 71(8):e31069.
10.1002/pbc.31069
CAS PubMed Google Scholar
26Atteby J, Moreira C, Traoré F, et al. Treatment of Wilms tumor in sub-Saharan Africa: results of the Second French African Pediatric Oncology Group study. J Glob Oncol. 2019; 5: 1-8. doi:10.1200/jgo.18.00204
10.1200/jgo.18.00204
Web of Science® Google Scholar
27Appeadu-Mensah W, Mdoka C, Alemu S, et al. Surgical aspects and outcomes after nephrectomy for Wilms tumour in sub-Saharan Africa. A report from Wilms Africa Phase II—CANCaRe Africa. Pediatr Blood Cancer. 2024:e31134. doi:10.1002/pbc.31134
10.1002/pbc.31134
PubMed Google Scholar

Citing Literature

Volume71, Issue11

November 2024

e31300

This article also appears in:

CANCaRe Africa

Effectiveness of a Wilms tumour treatment guideline adapted to local circumstances in sub-Saharan Africa: A report from Wilms Africa Phase II—CANCaRe Africa

Abstract

Background

Methods

Results

Conclusion

CONFLICT OF INTEREST STATEMENT

Open Research

DATA AVAILABILITY STATEMENT

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Effectiveness of a Wilms tumour treatment guideline adapted to local circumstances in sub-Saharan Africa: A report from Wilms Africa Phase II—CANCaRe Africa

Abstract

Background

Methods

Results

Conclusion

CONFLICT OF INTEREST STATEMENT

Open Research

DATA AVAILABILITY STATEMENT

REFERENCES

Citing Literature

References

Related

Information